A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis

20257 citationsJournal Articlehybrid Open Access

Authors

Once-monthly oral ibrexafungerp was effective and well-tolerated in participants with recurrent vulvovaginal candidiasis.

Good health and well-being

Published in: American Journal of Obstetrics and Gynecology

Volume 233, Issue 6, pp. 617.e1-617.e18

Field-Weighted Citation Impact: 8.52